• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

3.850 -0.070 (-1.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116,913
Open 3.860
Bid (Size) 3.810 (200)
Ask (Size) 4.120 (2,100)
Prev. Close 3.920
Today's Range 3.730 - 3.950
52wk Range 2.850 - 7.750
Shares Outstanding 20,161,073
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 ↗
Today 15:02 EDT
CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results... 
Via MarketBeat
News headline image
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
September 10, 2026
From CAMP4 Therapeutics
Via GlobeNewswire

Performance

YTD
-35.8%
-35.8%
1 Month
-7.2%
-7.2%
3 Month
-13.3%
-13.3%
6 Month
-3.7%
-3.7%
1 Year
+25.4%
+25.4%

More News

Read More
News headline image
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
September 08, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
September 01, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 13, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 04, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗
May 31, 2026
Via The Motley Fool
Topics Initial Public Offering
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 07, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
March 06, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 05, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From CAMP4 Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is CAMP4 Therapeutics Corporation - Common Stock publicly traded?
Yes, CAMP4 Therapeutics Corporation - Common Stock is publicly traded.
What exchange does CAMP4 Therapeutics Corporation - Common Stock trade on?
CAMP4 Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CAMP4 Therapeutics Corporation - Common Stock?
The ticker symbol for CAMP4 Therapeutics Corporation - Common Stock is CAMP on the Nasdaq Stock Market
What is the current price of CAMP4 Therapeutics Corporation - Common Stock?
The current price of CAMP4 Therapeutics Corporation - Common Stock is 3.850
When was CAMP4 Therapeutics Corporation - Common Stock last traded?
The last trade of CAMP4 Therapeutics Corporation - Common Stock was at 09/28/26 04:00 PM ET
What is the market capitalization of CAMP4 Therapeutics Corporation - Common Stock?
The market capitalization of CAMP4 Therapeutics Corporation - Common Stock is 77.62M
How many shares of CAMP4 Therapeutics Corporation - Common Stock are outstanding?
CAMP4 Therapeutics Corporation - Common Stock has 78M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap